Literature DB >> 19584812

Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization.

Frederick Arce1, Helen M Rowe, Benjamin Chain, Luciene Lopes, Mary K Collins.   

Abstract

Lentiviral vectors (LVs) are tools for in vivo gene delivery, to correct genetic defects or to deliver antigens for vaccination. It was reported that systemic injection of LVs in mice transduced cells in liver and spleen. Here we describe the reasons for, and consequences of, persistent gene expression in spleen. After 5 days of intravenous injection, a green fluorescence protein (GFP)-expressing LV was detected in lymphocytes, macrophages and all subsets of dendritic cells (DCs) in spleen. In the case of macrophages and DCs, the percentage of transduced cells increased between 5 and 30 days after injection. We used bromodeoxyuridine (BrdU) incorporation to show that the macrophages were largely nondividing, whereas the transduced DCs arose from dividing precursor cells and could be detected in spleen 2 months after injection. Expression of ovalbumin (OVA) in the LV reduced the number of transduced DCs in spleen after 30 days. However, the remaining transduced cells stimulated proliferation and activation of OVA-specific CD8(+) T cells transferred 2 months after LV injection. The mice also maintained cytolytic activity against OVA-pulsed targets. These results show that LVs transduce DC precursors, which maintain transduced DCs in spleen for at least 2 months, leading to prolonged antigen presentation and effective T-cell memory.

Entities:  

Mesh:

Year:  2009        PMID: 19584812      PMCID: PMC2835272          DOI: 10.1038/mt.2009.149

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  39 in total

Review 1.  Peripheral tolerance of CD8 T lymphocytes.

Authors:  William L Redmond; Linda A Sherman
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

2.  Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization.

Authors:  Yukai He; Jiying Zhang; Cara Donahue; Louis D Falo
Journal:  Immunity       Date:  2006-05       Impact factor: 31.745

3.  Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes.

Authors:  Shalin H Naik; Donald Metcalf; Annemarie van Nieuwenhuijze; Ian Wicks; Li Wu; Meredith O'Keeffe; Ken Shortman
Journal:  Nat Immunol       Date:  2006-05-07       Impact factor: 25.606

Review 4.  Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.

Authors:  Yukai He; David Munn; Louis D Falo
Journal:  Expert Rev Vaccines       Date:  2007-12       Impact factor: 5.217

5.  Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.

Authors:  Helen M Rowe; Luciene Lopes; Yasuhiro Ikeda; Ranbir Bailey; Isabelle Barde; Martin Zenke; Benjamin M Chain; Mary K Collins
Journal:  Mol Ther       Date:  2005-11-04       Impact factor: 11.454

Review 6.  Immunological memory and protective immunity: understanding their relation.

Authors:  R Ahmed; D Gray
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

7.  Successful treatment of UGT1A1 deficiency in a rat model of Crigler-Najjar disease by intravenous administration of a liver-specific lentiviral vector.

Authors:  Pascal van der Wegen; Rogier Louwen; Ali M Imam; Ruvalic M Buijs-Offerman; Maarten Sinaasappel; Frank Grosveld; Bob J Scholte
Journal:  Mol Ther       Date:  2005-12-05       Impact factor: 11.454

8.  A clonogenic bone marrow progenitor specific for macrophages and dendritic cells.

Authors:  Darin K Fogg; Claire Sibon; Chaouki Miled; Steffen Jung; Pierre Aucouturier; Dan R Littman; Ana Cumano; Frederic Geissmann
Journal:  Science       Date:  2005-12-01       Impact factor: 47.728

9.  Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response.

Authors:  Reinhard Obst; Hisse-Martien van Santen; Diane Mathis; Christophe Benoist
Journal:  J Exp Med       Date:  2005-05-16       Impact factor: 14.307

10.  Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice.

Authors:  Antonia Follenzi; Manuela Battaglia; Angelo Lombardo; Andrea Annoni; Maria Grazia Roncarolo; Luigi Naldini
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

View more
  17 in total

Review 1.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation.

Authors:  Jocelyn T Kim; Yarong Liu; Rajan P Kulkarni; Kevin K Lee; Bingbing Dai; Geoffrey Lovely; Yong Ouyang; Pin Wang; Lili Yang; David Baltimore
Journal:  Sci Immunol       Date:  2017-07-21

Review 3.  Tissue-resident dendritic cells and diseases involving dendritic cell malfunction.

Authors:  Keqiang Chen; Ji Ming Wang; Ruoxi Yuan; Xiang Yi; Liangzhu Li; Wanghua Gong; Tianshu Yang; Liwu Li; Shaobo Su
Journal:  Int Immunopharmacol       Date:  2016-02-22       Impact factor: 4.932

4.  HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.

Authors:  Karine Breckpot; David Escors; Frederick Arce; Lucienne Lopes; Katarzyna Karwacz; Sandra Van Lint; Marleen Keyaerts; Mary Collins
Journal:  J Virol       Date:  2010-03-17       Impact factor: 5.103

5.  Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.

Authors:  Therese Liechtenstein; Noemi Perez-Janices; Idoia Blanco-Luquin; Cleo Goyvaerts; Julia Schwarze; Ines Dufait; Alessio Lanna; Mark De Ridder; David Guerrero-Setas; Karine Breckpot; David Escors
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

6.  Vaccination with lentiviral vector expressing the nfa1 gene confers a protective immune response to mice infected with Naegleria fowleri.

Authors:  Jong-Hyun Kim; Hae-Jin Sohn; Jinyoung Lee; Hee-Jong Yang; Yong-Joon Chwae; Kyongmin Kim; Sun Park; Ho-Joon Shin
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

7.  Patients with cystic fibrosis have inducible IL-17+IL-22+ memory cells in lung draining lymph nodes.

Authors:  Yvonne R Chan; Kong Chen; Steven R Duncan; Kira L Lathrop; Joseph D Latoche; Alison J Logar; Derek A Pociask; Brendon J Wahlberg; Prabir Ray; Anuradha Ray; Joseph M Pilewski; Jay K Kolls
Journal:  J Allergy Clin Immunol       Date:  2012-07-11       Impact factor: 10.793

8.  Targeting lentiviral vectors for cancer immunotherapy.

Authors:  Frederick Arce; Karine Breckpot; Mary Collins; David Escors
Journal:  Curr Cancer Ther Rev       Date:  2011-11

9.  Retroviral and lentiviral vectors for the induction of immunological tolerance.

Authors:  Inès Dufait; Therese Liechtenstein; Alessio Lanna; Christopher Bricogne; Roberta Laranga; Antonella Padella; Karine Breckpot; David Escors
Journal:  Scientifica (Cairo)       Date:  2012-12

10.  4-1BB ligand activates bystander dendritic cells to enhance immunization in trans.

Authors:  Douglas C Macdonald; Alastair Hotblack; Saniath Akbar; Gary Britton; Mary K Collins; William C Rosenberg
Journal:  J Immunol       Date:  2014-10-10       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.